

Rx FOR SUCCESS Monoclonal Glammopathy

Plasma cells are a special form of lymphocyte (one of the classes of white blood cells) involved in immune function and found in the bone marrow. The immune system protects the body from infection by forming antibodies. Plasma cells can undergo malignant change with an increase in number (i.e., multiple myeloma, plasmacytoma) or with an increase in the production of immunoglobulin (lg) molecule, (i.e., monoclonal gammopathy, Waldenstrom's macroglobulinemia, or amyloidosis). These disorders are uninsurable with the exception of plasmacytomas, a localized form that may be treated successfully, and monoclonal gammopathy discussed below.

Monoclonal Gammopathy may be due to the over production of the heavy chain part of Ig (heavy chain disease) or due to the over production of the light chain Ig (light chain disease).

Elevated Ig components are occasionally found in asymptomatic, healthy persons (1% of persons age 25 and 4% of those over 70). Those that remain unchanged for years may be "benign" and are referred to as benign monoclonal gammopathy or monoclonal gammopathy of undetermined significance (MGUS). Other individuals (10-15%), discovered by doing additional testing, have "premyeloma." It is impossible to predict the course of an individual who has monoclonal gammopathy, and clinical myeloma may take 20 years to manifest from the "premyeloma" phase.

The abnormal increase of plasma cells can cause bone lesions, proteinuria, high calcium, kidney failure, anemia, and infections.

UNDERWRITING CONSIDERATIONS		
MGUS Within one year of discovery	Postpone	
After one year, if multiple myeloma ruled out by adequate work up	Table B	
Multiple Myeloma	Decline	

To get an idea of how a client with Monclonal Gammopathy would be viewed in the underwriting process, use the Ask "Rx" pert Underwriter on the next page for an informal quote.

This material is designed to provide general information about the subject matter covered. It should be used with the understanding that we are not rendering legal, accounting, or tax advice. Such services should be provided by the client's professional advisors. Accordingly, any information in this document cannot be used by any taxpayer for purposes of avoiding penalties under the Internal Revenue Code.

This material is intended for insurance informational purposes only and is not personal medical advice for clients. Rates and availability will vary based on the satisfaction of our underwriting criteria. Underwriting rules are subject to change at our discretion. This marketing material is subject to an expiration date, and use of this material must be discontinued as of the expiration date.

Insurance issued by The Prudential Insurance Company of America and its affiliates, Newark, NJ.

NOT FOR CONSUMER USE. © 2013 Prudential Financial, Inc. and its related entities. 0192228-00002-00 Ed. 01/2013 Exp. 01/15/2015 Rx 072 Securities and Insurance Products: Not Insured by FDIC or Any Federal Government Agency. May Lose Value. Not a Deposit of or Guaranteed by Any Bank or Bank Affiliate.



Ask "Rx"pert Underwriter (Ask Our Expert)		
After reading the <i>Rx for Success</i> on Monoclonal Gammopathy, use this form to Ask "Rx" pert Underwriter for an informal quote.		
		Fax Sex
If your client has a history of Monoclonal Gammopathy, please answer the following:		
1. Please list date of first diagnosis	i.	
2. Was a bone biopsy done?		
☐ Yes. Please give details ☐ No		
3. Is your client on any medication	s?	
☐ Yes. Please give details ☐ No		
4. Please provide the clients most	recent readings for:	
□ BUN □ Creatinine		
5. Have the elevated protein (Ig) le	vels remained stable since diagnosis?	
☐ Yes. Please give details ☐ No		
6. Has your client smoked cigarette	es in the last 12 months?	
□ Yes □ No		
7. Does your client have any other major health problems (e.g., cancer, etc.)?		
☐ Yes. Please give details ☐ No		